tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

EYPT Stock Latest News

EyePoint Pharmaceuticals Raises $141M in Public Offering
Company AnnouncementsEyePoint Pharmaceuticals Raises $141M in Public Offering
3d ago
8K
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
3d ago
EYPT
EyePoint 11M share Spot Secondary priced at $12.00
PremiumThe Fly
EyePoint 11M share Spot Secondary priced at $12.00
5d ago
EYPT
Closing Bell Movers: BrightSpring Health up 6% on S&P 600 inclusion
PremiumThe Fly
Closing Bell Movers: BrightSpring Health up 6% on S&P 600 inclusion
5d ago
CVV
HWC
EyePoint $150M Spot Secondary; price range $12.00-$12.50
PremiumThe Fly
EyePoint $150M Spot Secondary; price range $12.00-$12.50
5d ago
EYPT
EyePoint announces $150M offering of common stock
PremiumThe FlyEyePoint announces $150M offering of common stock
5d ago
EYPT
EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program
Premium
Company Announcements
EyePoint Pharmaceuticals Launches Phase 3 DURAVYU Program
5d ago
8K
EYPT
EyePoint files automatic mixed securities shelf
Premium
The Fly
EyePoint files automatic mixed securities shelf
5d ago
EYPT
EyePoint initiates Duravyu program, announces preclinical vorolanib data
PremiumThe Fly
EyePoint initiates Duravyu program, announces preclinical vorolanib data
5d ago
EYPT
EyePoint reports inducement grants under NASDAQ listing rule
PremiumThe Fly
EyePoint reports inducement grants under NASDAQ listing rule
1M ago
EYPT
EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy
PremiumCompany Announcements
EyePoint Pharmaceuticals Completes Promising Study on EYP-1901 for Diabetic Retinopathy
2M ago
EYPT
EyePoint price target raised to $28 from $26 at Mizuho
PremiumThe Fly
EyePoint price target raised to $28 from $26 at Mizuho
2M ago
EYPT
EyePoint Pharma’s Earnings Call: Clinical Wins Amid Financial Challenges
PremiumCompany AnnouncementsEyePoint Pharma’s Earnings Call: Clinical Wins Amid Financial Challenges
2M ago
EYPT
EyePoint Pharma Advances DURAVYU Trials Amid Financial Challenges
Premium
Company Announcements
EyePoint Pharma Advances DURAVYU Trials Amid Financial Challenges
2M ago
EYPT
EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI
Premium
Ratings
EyePoint Pharmaceuticals: Promising Phase III Trials and Market Potential for Long-Acting TKI
2M ago
EYPT
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating
PremiumRatings
EyePoint Pharmaceuticals: Promising Phase 3 Trial Progress and Strategic Advancements Justify Buy Rating
2M ago
EYPT
EyePoint price target raised to $23 from $22 at H.C. Wainwright
PremiumThe Fly
EyePoint price target raised to $23 from $22 at H.C. Wainwright
2M ago
EYPT
EyePoint reports Q2 EPS (85c), consensus (80c)
PremiumThe Fly
EyePoint reports Q2 EPS (85c), consensus (80c)
2M ago
EYPT
EyePoint sees cash runway into 2027
PremiumThe Fly
EyePoint sees cash runway into 2027
2M ago
EYPT
Buy Rating for EyePoint Pharmaceuticals: Duravyu’s Competitive Edge and Reliability Drive Investment Confidence
PremiumRatingsBuy Rating for EyePoint Pharmaceuticals: Duravyu’s Competitive Edge and Reliability Drive Investment Confidence
3M ago
EYPT
Positive Buy Rating for EyePoint Pharmaceuticals Driven by Promising Clinical Trials and Market Valuation
Premium
Ratings
Positive Buy Rating for EyePoint Pharmaceuticals Driven by Promising Clinical Trials and Market Valuation
3M ago
EYPT
EyePoint’s wAMD study fully enrolled ahead of expectations, says RBC Capital
Premium
The Fly
EyePoint’s wAMD study fully enrolled ahead of expectations, says RBC Capital
3M ago
EYPT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >